Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(02): 173-181
DOI: 10.4103/ijmpo.ijmpo_24_17
Review Article

Metastatic Ewing’s Sarcoma: Revisiting the “Evidence on the Fence”

Nehal Khanna
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Avinash Pandey
Department of Medical Oncology, IGIMS, Patna, Bihar, India
,
Jyoti Bajpai
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Metastatic Ewing's sarcoma is a challenging disease for oncology care providers with wide spectrum of disease at presentation, widely varying approach to the treatment and varied outcomes. The paucity of randomized evidence is a barrier in developing a consensus. This perspective provides the evidence ”for and against” the benefit of aggressive approach including local and systemic therapy in patients presenting with metastatic Ewing's sarcoma and provide general recommendations so as to help select patients who will benefit with definitive intent treatment and also, avoid aggressive approach in patients with dismal outcome.

Keywords

Bone metastasis - curative - Ewing's sarcoma - lung metastasis - palliative


Publication History

Article published online:
06 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Nesbit Jr ME, Gehan EA, Burgert Jr EO, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clinical Oncology 1990;8:1664-74.
  • 2 Jürgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European cooperative trial. Cancer 1988;61:23-32.
  • 3 Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: A EUROCARE Working Group study. J Clinical Oncology 2005;23:3742-51.
  • 4 Cotterill S, Ahrens S, Paulussen M, Jurgens H, Voute P, Gadner H, et al. Prognostic factors in Ewing's tumor of bone: Aanalysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clinical Oncology 2000;18:3108-14.
  • 5 Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010;116:443-50.
  • 6 Paulussen M, Braun-Munzinger G, Burdach S, Deneke S, Dunst J, Fellinger E, et al. Results of treatment of primary exclusively pulmonary metastatic Ewing sarcoma. A retrospective analysis of 41 patients. Klinische Padiatrie 1992;205:210-6.
  • 7 Paulussen M, Ahrens S, Craft A, Dunst J, Fröhlich B, Jabar S, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clinical Oncology 1998;16:3044-52.
  • 8 Casey DL, Alektiar KM, Gerber NK, Wolden SL. Whole lung irradiation for adults with pulmonary metastases from Ewing sarcoma. International Journal of Radiation Oncology* Biology* Physics 2014;89:1069-75.
  • 9 Spunt SL, McCarville MB, Kun LE, Poquette CA, Cain AM, Brandao L, et al. Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis. J Pediatric Hematology/Oncology 2001;23:93-8.
  • 10 Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clinical Oncology 2010;28:3284-91.
  • 11 Attard-Montalto S, Kingston J, Eden O, Plowman P. Late follow-up of lung function after whole lung irradiation for Wilms' tumour. The British J Radiology 1992;65:1114-8.
  • 12 Weiner DJ, Maity A, Carlson CA, Ginsberg JP. Pulmonary function abnormalities in children treated with whole lung irradiation. Pediatric Blood and Cancer 2006;46:222-7.
  • 13 Harting MT, Blakely ML, Jaffe N, Cox CS, Hayes-Jordan A, Benjamin RS, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatric Surgery 2006;41:194-9.
  • 14 Letourneau PA, Shackett B, Xiao L, Trent J, Tsao KJ, Lally K, et al. Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. J Pediatric Surgery 2011;46:332-5.
  • 15 Heij HA, Vos A, De Kraker J, Voute P. Prognostic factors in surgery for pulmonary metastases in children. Surgery 1994;115:687-93.
  • 16 Tronc F, Conter C, Marec-Berard P, Bossard N, Remontet L, Orsini A, et al. Prognostic factors and long-term results of pulmonary metastasectomy for pediatric histologies. European Journal of Cardio-Thoracic Surgery 2008;34:1240-6.
  • 17 Cangir A, Vietti TJ, Gehan EA, Burgert EO, Thomas P, Tefft M, et al. Ewing's sarcoma metastatic at diagnosis results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-93.
  • 18 Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, et al. Primary metastatic Ewing's family tumors: Results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Annals of Oncology 2012;23:2970-6.
  • 19 Treasure T, Fiorentino F, Scarci M, Møller H, Utley M. Pulmonary metastasectomy for sarcoma: A systematic review of reported outcomes in the context of Thames Cancer Registry data. BMJ Open 2012;2:e001736.
  • 20 Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Annals of Oncology 1998;9:275-81.
  • 21 Paulino AC, Mai WY, Teh BS. Radiotherapy in metastatic Ewing sarcoma. American J Clinical Oncology 2013;36:283-6.
  • 22 Casey DL, Wexler LH, Meyers PA, Magnan H, Chou AJ, Wolden SL. Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma. Pediatric Blood and Cancer 2015;62:445-9.
  • 23 Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. Journal of Clinical Oncology 1998;16:3628-33.
  • 24 Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG# 8346. International Journal of Radiation Oncology* Biology* Physics 1998;42:125-35.
  • 25 Craft A, Cotterill S, Bullimore J. Long-term results from the first UKCCSG Ewing's tumour study (ET-1). European J Cancer 1997;33:1061-9.
  • 26 Sandoval C, Meyer WH, Parham DM, Kun LE, Hustu HO, Luo X, et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: The St. Jude Children's Research Hospital experience, 1962 to 1992. Pediatric Blood and Cancer 1996;26:180-5.
  • 27 Demeocq F, Oberlin O, Benz-Lemoine E, Boilletot A, Gentet J, Zucker J, et al. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: Preliminary results A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemotherapy and Pharmacology 1989;24:S45-S7.
  • 28 Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst Jr, et al. Results of the EICESS-92 Study: Two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clinical Oncology 2008;26:4385-93.
  • 29 Biswas B, Rastogi S, Khan S, Shukla N, Deo S, Agarwala S, et al. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: A single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clinical Oncology 2014;26:722-9.
  • 30 Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clinical Oncology 1995;13:2796-804.
  • 31 Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: A feasibility study at St. Jude Children's Research Hospital. J Clinical Oncology 1999;17:180-90.
  • 32 Brunetto AL, Castillo LA, Petrilli AS, Macedo CD, Boldrini E, Costa C, et al. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian Collaborative Study Group for Ewing Sarcoma Family Tumors–EWING1. Pediatric Blood and Cancer 2015;62:1747-53.
  • 33 Womer R, Daller R, Fenton JG, Miser J. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. European J Cancer 2000;36:87-94.
  • 34 Czyzewski EAD, Goldman S, Mundt AJ, Nachman J, Rubin C, Hallahan DE. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study. International Journal of Radiation Oncology* Biology* Physics 1999;44:569-77.
  • 35 Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplantation 1999;24:609-15.
  • 36 Burdach S, Jürgens H, Peters C, Nürnberger W, Mauz-Körholz C, Körholz D, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clinical Oncology 1993;11:1482-8.
  • 37 Burdach S, Van Kaick B, Laws H, Ahrens S, Haase R, Körholz D, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors: An update after long-term follow-up from two centers of the European Intergroup Study EICESS. Annals of Oncology 2000;11:1451-62.
  • 38 Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clinical Oncology 1993;11:1911-8.
  • 39 Bader JL, Horowitz ME, Dewan R, Watkins E, Triche TJ, Tsokos M, et al. Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiotherapy and Oncology 1989;16:189-201.
  • 40 Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors. Pediatric Blood and Cancer 2000;34:328-37.
  • 41 Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: A study by the Societe Francaise des Cancers de l'Enfant. J Clinical Oncology 2006;24:3997-4002.
  • 42 Meyers PA, Krailo MD, Ladanyi M, Chan K-W, Sailer SL, Dickman PS, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clinical Oncology 2001;19:2812-20.
  • 43 Ladenstein R, Lasset C, Pinkerton R, Zucker J, Peters C, Burdach S, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: A report from the EBMT Solid Tumour Registry. Bone Marrow Transplantation 1995;15:697-705.
  • 44 Bölling T, Schuck A, Paulussen M, Dirksen U, Ranft A, Könemann S, et al. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Strahlentherapie und Onkologie 2008;184:193-7.
  • 45 Margolis LW, Phillips TL. Whole-lung irradiation for metastatic tumor. Radiology 1969;93:1173-9.
  • 46 Rosen G, Wollner N, Tan C, Wu S, Hajdu S, Cham W, et al. Disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 1974;33:384-93.
  • 47 Dunst J, Paulussen M, Jürgens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft[et al] 1993;169:621-3.
  • 48 Karnak I, Şenocak ME, Kutluk T, Tanyel FC, Büyükpamukçu N. Pulmonary metastases in children: An analysis of surgical spectrum. European J Pediatric Surgery 2002;12:151-8.
  • 49 Lanza L, Miser J, Pass H, Roth J. The role of resection in the treatment of pulmonary metastases from Ewing's sarcoma. The J Thoracic and Cardiovascular Surgery 1987;94:181-7.
  • 50 Hayes F, Thompson E, Parvey L, Rao B, Kun L, Parham D, et al. Metastatic Ewing's sarcoma: Remission induction and survival. Journal of Clinical Oncology 1987;5:1199-204.
  • 51 Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. New England J Medicine 2003;348:694-701.
  • 52 Wexler LH, DeLaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996;78:901-11.
  • 53 Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. J Clinical Oncology 2004;22:2873-6.
  • 54 Atra A, Whelan J, Calvagna V, Shankar A, Ashley S, Shepherd V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplantation 1997;20:843-6.
  • 55 Laurence V, Pierga J-Y, Barthier S, Babinet A, Alapetite C, Palangié T, et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. American J Clinical Oncology 2005;28:301-9.
  • 56 Miser JS, Kinsella T, Triche T, Tsokos M, Forquer R, Wesley R, et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: Six months of intensive combined modality therapy without maintenance. J Clinical Oncology 1988;6:484-90.
  • 57 Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clinical Oncology 2001;19:870-80.